NCT02814097已完成2 期
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 9
- 主要终点
- Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groups
研究概览
简要总结
This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥45 and <80 years.
- •Symptomatic heart failure (i.e. NYHA II or III) due to HFpEF for at least 6 months prior to study start
- •Evidence of HFpEF: LVEF ≥45% and E/e´>10 and NT-pro-BNP >220 pg/ml (sinus rhythm) / > 600 pg/mL (atrial fibrillation)
- •An exercise-induced increase in E/e' of at least 1.5 units during stress echocardiography assessment.
- •Heart failure is considered to be stable, in the judgment of the investigator, and no hospitalization for HFpEF or changes in dose regimen of pharmacologic treatment for HF has occurred within 1 month prior to the Screening Visit.
- •Treatment with appropriate pharmacologic therapy to manage underlying risk factors according to current guidelines.
- •Women of childbearing potential must agree to use 1 of the following methods of birth control from the date they sign the ICF until two months after the last dose of study medication:
- •a) Abstinence, b) surgically sterilized male partner, or c) barrier method And hormonal contraception
- •Women of child-bearing potential must have a negative serum pregnancy test at baseline
- •Willing and able to provide signed informed consent form (ICF) prior to participation in any study-related procedures
排除标准
- •Probable alternative diagnoses that in the opinion of the investigator could account for the patient's symptoms e.g. severe pulmonary dysfunction or severe asthma
- •LVEF <45% (at the moment of enrollment or in medical history)
- •Coronary or peripheral revascularization procedures, valvular procedures, OR any major surgical procedure within 3 months prior to the Screening Visit.
- •Acute coronary syndrome (ACS), stroke or transient ischemic attack (TIA) within 3 months prior to the Screening Visit.
- •Uncontrolled hypertension defined as a systolic blood pressure (BP) >160 mm Hg or a diastolic BP >100 mm Hg on at least 2 consecutive readings that will require a change in anti-hypertensive treatment during the study period.
- •Active cancer or undergoing chemotherapy within previous 6 months
- •Total bilirubin >2x the upper limit of normal (ULN) in the absence of Gilbert's Syndrome (M. Meulengracht) and liver enzymes (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] and/or alkaline phosphatase) elevation >3xULN
- •Estimated glomerular filtration rate <30 mL/min, by MDRD
- •Known active drug or alcohol abuse within 1 year of the Screening Visit.
- •Use of other investigational drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment
- •Treatment with spironolactone or eplerenone for less than 3 months at study start
- •Treatment with dabigatran
- •Treatment with valsartan/sacubitril
- •Female subjects who are pregnant, planning to become pregnant, or lactating.
研究组 & 干预措施
40 mg elamipretide
Experimental
40 mg elamipretide once daily for 28 consecutive days
干预措施: elamipretide (Drug)
Placebo
Placebo Comparator
Placebo once daily for 28 consecutive days
干预措施: Placebo (Drug)
结局指标
主要结局
Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groups
时间窗: 4 weeks
次要结局
- Compare the change in 6-minute walking distance, between the elamipretide and placebo groups at the end of the 4-week treatment period(4 weeks)
- Compare the change in NT-proBNP, between the elamipretide and placebo groups at the end of the 4-week treatment period(4 weeks)
- Compare the percent of patients on elamipretide versus placebo presenting with TEAEs and SAEs, including changes in biomarkers of myocardial damage and changes in markers of renal function(4 weeks)
- Compare the change at rest and during submaximal stress in LV systolic global longitudinal strain (GLS) between the elamipretide and placebo groups at the end of the 4-week treatment period(4 weeks)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic Steatohepatitis (NASH)NCT02927314Can-Fite BioPharma60
已完成
2 期
Efficacy and Safety of Oral BT-11 in Ulcerative ColitisUlcerative ColitisNCT03861143NImmune Biopharma198
已完成
2 期
Broad-spectrum Rapid Antidote: Varespladib Oral for SnakebiteSnakebitesEnvenomingEnvenoming, SnakeEnvenomation, SnakeNCT04996264Ophirex, Inc.95
已完成
2 期
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/BBotulism VaccineNCT00764634DynPort Vaccine Company LLC, A GDIT Company440
Unknown
2 期
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19Covid19NCT04780685Stemedica Cell Technologies, Inc.40